ClinicalTrials.gg
RecruitingNCT07707245RESPIROUpdated Jul 16, 2026

Identification of Diagnostic and Prognostic Biomarkers in the Pathological Continuum of Bronco Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis and Pulmonary Neoplasia

An interventional study of Peripheral Blood Collection in COPD, Idiopathic Pulmonary Fibrosis (IPF) and Lung Cancer, sponsored by Fondazione Don Carlo Gnocchi ETS. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Fondazione Don Carlo Gnocchi ETS · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 280 studies in Pulmonary Disease, Chronic Obstructive with a site in Italy — 42 open to participants now, 48 under way, 8 of them phase 3. Pulmonary Disease, Chronic Obstructive · Italy.

Planned enrollment
126th of 212
120 · median 245
Started
2026
with 6 others
No phase
77 of 280
17 open now
Primary completion
2027-11
later than 33 of 47 live
Registered
277th of 280
by date

Among the 280 studies in Pulmonary Disease, Chronic Obstructive with a site in Italy, this one is the 126th largest by planned enrollment of the 212 interventional ones that give a count, is one of 7 that started in 2026, is one of 77 with no phase, reaches primary completion later than 33 of the 47 other live ones, and was the 277th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

42 of the 280 studies in Pulmonary Disease, Chronic Obstructive with a site in Italy are open now. Recruiting first, the newest first:

36 more — sign in →

All 42 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 280 studies in Pulmonary Disease, Chronic Obstructive with a site in Italy, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the association between inflammatory, immunological, genetic, and epigenetic biomarkers measured at enrollment and the clinical, functional, and phenotypic characteristics of patients with chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and lung cancer.

Secondary Objective:

To assess the prognostic value of the identified biomarkers by evaluating their ability to predict clinical outcomes at 12 months.

Primary Outcome Measure:

Association between baseline inflammatory, immunological, genetic, and epigenetic biomarkers and disease-specific clinical, functional, and phenotypic characteristics assessed at enrollment, including:

COPD: current or former smokers, stratified according to the predominant phenotype (emphysema or bronchiolitis); IPF: rapid progressors, slow progressors, and patients with combined pulmonary fibrosis and emphysema (CPFE); Lung cancer: current smokers, former smokers who quit less than 15 years before enrollment, former smokers who quit 15 years or more before enrollment, and never-smokers.

Secondary Outcome Measure:

Predictive performance of baseline inflammatory, immunological, genetic, and epigenetic biomarkers for 12-month clinical outcomes.

Read the detailed description

This is a non-profit, interventional pilot study without an investigational medicinal product. The study consists of two phases: a prospective phase (Phase I) and a retrospective phase (Phase II).

Study Timeline

The overall study duration will be 30 months, as follows:

Patient enrollment and biological sample collection: 18 months. Follow-up visit: 12 months after enrollment for each participant. Laboratory analyses: 20 months. Statistical analyses: at Month 24 (primary endpoint) and at Month 30 (12-month follow-up analyses).

Phase I - Prospective

Participants enrolled in the prospective phase will undergo study assessments according to the following schedule:

T0 (Baseline): Enrollment. T1: 12-month follow-up after enrollment. Clinical and laboratory data will be collected at baseline (T0) and at the 12-month follow-up visit (T1), as specified in the study schedule of assessments.

Phase II - Retrospective Archived tissue samples will be used.

Study Setting Phase I

The prospective phase will enroll:

40 patients with chronic obstructive pulmonary disease (COPD), current or former smokers; 40 patients with idiopathic pulmonary fibrosis (IPF), current or former smokers; 30 never-smoking patients with resectable Stage I or II lung adenocarcinoma undergoing surgical resection; 30 current or former smoking patients with resectable Stage I, II, or III lung adenocarcinoma undergoing surgical resection.

Patients with COPD and IPF will be recruited during outpatient visits. Patients with lung cancer will be recruited either during the preoperative outpatient evaluation or upon hospital admission for surgical treatment.

Phase II Archived tissue biopsy specimens collected during routine clinical practice, either fresh-frozen or formalin-fixed paraffin-embedded (FFPE).

The retrospective cohort will include samples from:

40 patients with COPD; 40 patients with IPF; 30 never-smoking patients with Stage I or II lung adenocarcinoma; 30 smoking patients with Stage I or II lung adenocarcinoma. Study Procedures Phase I - Prospective

Following written informed consent, all participants will undergo collection of approximately 40 mL of peripheral blood:

Three EDTA tubes of whole blood; Two serum tubes.

Peripheral blood mononuclear cells (PBMCs) will be isolated by Ficoll-Paque Plus density-gradient centrifugation, washed with phosphate-buffered saline (PBS), counted, and processed as follows:

Immunophenotypic characterization of innate and adaptive immune cell markers using monoclonal antibody staining and flow cytometry; In vitro stimulation with culture medium alone and with lipopolysaccharide (LPS) plus nigericin to evaluate NLRP3 inflammasome activation; Cryopreservation of a PBMC aliquot in dimethyl sulfoxide (DMSO) at -140°C until analysis.

Serum samples will undergo:

Automated extraction of microRNAs using commercially available column-based extraction kits; Reverse transcription into complementary DNA (cDNA), with storage at -20°C until analysis.

PBMCs will also be used for:

Genomic DNA extraction using the phenol-chloroform method, followed by storage at -20°C until analysis.

Phase II - Retrospective

Archived fresh-frozen and FFPE tissue samples collected during routine clinical care will be retrieved from the participating biobank and pathology department.

Patients whose biological samples are eligible for inclusion will be contacted to obtain specific informed consent for the use of their archived specimens for the present research project. Only samples from participants providing written informed consent will be included.

From FFPE tissue samples:

Genomic DNA will be extracted using the QIAamp DNA FFPE Tissue Kit (Qiagen) and an automated extraction platform, then stored at -20°C until analysis.

MicroRNAs will be extracted using the RNeasy FFPE Kit (Qiagen) and an automated extraction platform, reverse-transcribed into cDNA, and stored at -20°C until analysis.

In addition to the translational research analyses specified in the protocol, results from routine molecular diagnostic testing previously performed on retrospective lung tumor specimens will also be collected. These include PD-L1 expression analysis in squamous cell carcinomas and Myriapod next-generation sequencing (NGS) mutational profiling (DNA and RNA) in lung adenocarcinomas. These molecular variables will be included as covariates in the statistical analyses.

03

Conditions studied

  • COPD
  • Idiopathic Pulmonary Fibrosis (IPF)
  • Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years.
  • Clinical diagnosis of: (COPD), current or former smokers; and/or Idiopathic Pulmonary Fibrosis (IPF), current or former smokers; and/or Resectable lung adenocarcinoma (Stage I-III, according to clinical indication for surgical resection).
  • Ability to comply with study procedures and follow-up visits.

Exclusion criteria

Exclusion Criteria:

  • Inability or unwillingness to provide .
  • Active respiratory infection or acute exacerbation of or IPF at the time of enrollment.
  • Previous or concomitant malignant disease (except non-melanoma skin cancer) that could interfere with study objectives.
  • Prior systemic or anti-inflammatory therapy that may significantly alter immune profiling within a defined (if applicable per protocol).
  • Severe comorbid conditions limiting or ability to complete follow-up (e.g., advanced heart failure, severe renal or hepatic disease).

Inadequate biological sample quality or impossibility to obtain required blood samples.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Biomarker Assessment

    Participants with chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), or resectable lung carcinoma will undergo peripheral blood collection at baseline for inflammatory, immunological, genetic, and epigenetic biomarker analyses. Clinical and functional data will be collected at baseline, and participants will undergo a 12-month follow-up to evaluate the prognostic value of the identified biomarkers.

    Procedure: Peripheral Blood Collection

Interventions

  • ProcedurePeripheral Blood Collection

    Peripheral venous blood collection (approximately 40 mL) for inflammatory, immunological, genetic, and epigenetic biomarker analyses, including PBMC isolation, serum collection, genomic DNA extraction, and microRNA analysis.

06

What researchers measure

Primary outcomes

  1. Innate immunity

    Macrophages, monocytes, neutrophils, and dendritic cells (for all: % of total blood cells)

    Time frame: Baseline

  2. Genetic polymorphisms

    KIR, HLA-Cw, VDR, GC1, IL-1β, IL-1Ra, IL-6, IL-10, IL-13, IL-18, TGF-β1, TNF-α (for all: presence or absence)

    Time frame: baseline

  3. Adaptive immunity

    CTLA-4, PD-1, PDL-1, PDL-2, Galectin-9, LAG-3, TIM-3, VISTA, TIGIT, IL-10, TGF-β, IL-13, IL-35, IL-17 IL-21, IL-1β, IL-6, IL-23, IL-22 (for all: ng/ml)

    Time frame: baseline

  4. serum microRNAs

    serum miR-155-5p, miR-146a-5p, miR-181a-5p, miR-223-3p, miR-431-5p, miR-149-3p, miR-335-5p and miR-206 (for all: copies/ul)

    Time frame: baseline

  5. Forced Expiratory Volume in 1 second

    Forced Expiratory Volume in 1 second (FEV1) (%)

    Time frame: baseline and after 12 months

  6. VC

    Vital Capacity (VC) (%)

    Time frame: baseline and after 12 months

  7. Total Lung Capacity

    Total Lung Capacity (TLC) (%)

    Time frame: baseline and after 12 months

  8. Inspiratory Capacity

    Inspiratory Capacity (IC) (%)

    Time frame: baseline and after 12 months

  9. Expiratory Reserve Volume

    Expiratory Reserve Volume (ERV) %)

    Time frame: Baseline and after 12 months

  10. Residual Volume

    Residual Volume (RV) (%)

    Time frame: Baseline and after 12 months

  11. Diffusing Capacity of the Lung for Carbon Monoxide / Alveolar Volume

    Diffusing Capacity of the Lung for Carbon Monoxide / Alveolar Volume (DLCO/AV) (%)

    Time frame: Baseline and after 12 months

  12. Blood gas analysis - PaO2

    PaO2 (mmHg)

    Time frame: Baseline and after 12 months

  13. Blood gas analysis - PaCO2

    PaCO2 (mmHg)

    Time frame: baseline and after 12 months

  14. Test 6 minute walk

    Test 6 minute walk (metres)

    Time frame: baseline and after 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — IPD will not be shared due to privacy and confidentiality concerns related to the detailed clinical and multi-omics nature of the dataset and the potential risk of re-identification in rare or stratified patient subgroups.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Nov 2027, 19 months after the start.

Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 19 months is below that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2026
First posted
Jul 16, 2026
StartActual
Apr 22, 2026
Primary completionEst.
Nov 30, 2027
CompletionEst.
Oct 30, 2028
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07707245
Lead sponsor
Fondazione Don Carlo Gnocchi ETS
Collaborators
Trust Franco e Piero Gazzarrini
Responsible party
Sponsor
First posted
Jul 16, 2026
Start date
Apr 22, 2026
Primary completion
Nov 30, 2027 (estimated)
Completion
Oct 30, 2028 (estimated)
Last update
Jul 16, 2026

Study contacts

Mario Clerici, MD
Contact
mario.clerici@unimi.it
+39024030801
Simone Agostini, PhD
Contact
sagostini@dongnocchi.it
+390240308375
Mario Clerici, MD
principal investigator · IRCCS Fondazione Don Carlo Gnocchi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion